By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Corvus Pharmaceuticals 

863 Mitten Road, Suite 102

Burlingame  California    U.S.A.
Phone: 650-900-4520 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Corvus Pharma


Start Up

Company News
Corvus Pharma Announces Interim Results Demonstrating Anti-Tumor Activity Of CPI-444 In Renal And Lung Cancer Patients Resistant Or Refractory To Prior PD-(L)1 Treatment 6/5/2017 10:29:31 AM
Corvus Pharma And Monash University Enter Into Exclusive License Agreement For Novel Immuno-Oncology Program 5/9/2017 8:18:28 AM
Corvus Pharma Reports First Quarter 2017 Financial Results and Provides Business Update 5/5/2017 11:37:56 AM
Corvus Pharma Expands CPI-444 Clinical Collaboration With Genentech (RHHBY) 5/2/2017 8:07:02 AM
Corvus Pharma Announces Interim Results From Ongoing Phase I/Ib Study Demonstrating Safety And Clinical Activity Of Lead Checkpoint Inhibitor CPI-444 In Patients With Advanced Cancers 4/4/2017 11:37:56 AM
Corvus Pharma To Reschedule R&D Day Due To Severe Winter Storm In The New York Tri-State Area 3/13/2017 8:16:47 AM
Corvus Pharma Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Business Update 3/10/2017 8:52:25 AM
Vernalis PLC (VNLPY.PK) Achieves A $3 Million Milestone Payment From Corvus Pharma 2/14/2017 9:26:17 AM
Corvus Pharma Announces Expansion Of Renal Cell Carcinoma Cohort In Ongoing Phase I/Ib Clinical Study Of Lead Checkpoint Inhibitor CPI-444 1/10/2017 6:56:57 AM
Corvus Pharma Announces Preliminary Phase 1/1b Clinical Data With Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety And Evidence Of Anti-Tumor Activity As A Single Agent In Patients With Advanced Refractory Cancers 11/11/2016 9:04:42 AM